步长制药：公司近两年已实现欧洲市场出口布局

Core Viewpoint - The company has established an export presence in the European market over the past two years, primarily through partnerships in the Eurasian Economic Union countries [1] Group 1: Market Expansion - In 2024, the company's subsidiary Luzhou Buchang will sign an agreement with Russia's LANCET company to authorize the registration and commercialization of injectable BC001 in the region [1] - The company has successfully sold multiple traditional Chinese medicine products to dozens of countries and regions worldwide [1] Group 2: Regulatory Progress - The company is currently advancing the EU COS certification for its main products in core EU countries, with future sales progress to be monitored through special responses and related announcements [1]